Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer J Clin. 2015;65:87-108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Travis WD. Pathology of lung cancer. Clinics Chest Med. 2011;32:669-92. doi:10.1016/j.ccm.2011.08.005.
   PubMed Web of Science ®Google Scholar
• Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039-49. doi:10.1200/jco.2012.45.3753.
   PubMed Web of Science ®Google Scholar
• Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909-14. doi:10.1158/0008-5472.can-11-3406.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13 Suppl 1:5-13. doi:10.1634/theoncologist.13-S1-5.
   PubMed Web of Science ®Google Scholar
• Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Nintedanib in non-small cell lung cancer: from preclinical to approval. Therapeutic Adv Respir Dis. 2015;9:164-72. doi:10.1177/1753465815579608.
   PubMed Web of Science ®Google Scholar
• Larkins E, Scepura B, Blumenthal GM, Bloomquist E, Tang S, Biable M, Kluetz P, Keegan P, Pazdur R. U.S. food and drug administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy. Oncologist. 2015;20:1320-5. doi:10.1634/theoncologist.2015-0221.
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102:1374-80. doi:10.1111/j.1349-7006.2011.01939.x.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448-54. doi:10.1200/jco.2015.63.5995.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shi M, Huang C, Liu X, Xiong JP, Chen G, et al A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol. 2012; 15(30) Suppl: 7548; doi:10.1200/jco.2012.30.15_suppl.7548.
   Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-91. doi:10.1038/nrc2403.
   PubMed Web of Science ®Google Scholar
• Ding L, Li QJ, You KY, Jiang ZM, Yao HR. The use of apatinib in treating nonsmall-cell lung cancer: Case report and review of literature. Medicine. 2016;95:e3598. doi:10.1097/md.0000000000003598.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219-25. doi:10.1200/jco.2013.48.8585.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, et al Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. doi:10.1186/1471-2407-10-529.
   PubMed Web of Science ®Google Scholar
• Song Z, Yu X, Lou G, Shi X, Zhang Y. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Therapy. 2017;10:1821-5. doi:10.2147/ott.s113435.
   PubMed Web of Science ®Google Scholar
• Lin C, Wang S, Xie W, Zheng R, Gan Y, Chang J. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget. 2016;7:59236-44. doi:10.18632/oncotarget.10985.
   PubMed Web of Science ®Google Scholar
• Fang SC, Zhang HT, Zhang YM, Xie WP. Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. Onco Targets Therapy. 2017;10:447-52. doi:10.2147/ott.s126613.
   PubMed Web of Science ®Google Scholar
• Sandler A GR, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel–carboplatin alone or with Bevacizumab for non–small-cell lung cancer. New England J Med. 2007; 356:318. doi:10.1056/NEJMx070002.
   Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, et al Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143-55. doi:10.1016/s1470-2045(13)70586-2.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, et al Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet (London, England). 2014;384:665-73. doi:10.1016/s0140-6736(14)60845-x.
   PubMed Web of Science ®Google Scholar
• Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70:7981-91. doi:10.1158/0008-5472.can-10-0111.
   PubMed Web of Science ®Google Scholar
• Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochemical Pharmacol. 2012; 83:586-97. doi:10.1016/j.bcp.2011.12.007.
   PubMed Web of Science ®Google Scholar